AZ ups emerging markets bet with $200M plant in China

AstraZeneca ($AZN) has announced a $200 million investment to build a pharma manufacturing plant in China Medical City, Jiangsu Province. The company says the financial commitment is its largest ever in a single manufacturing facility.

The plant is expected to produce both intravenous and oral solid medicines.

The new plant "will complement our efforts to meet the medical needs of Chinese patients with medicines that are locally produced," AZ China president Mark Mallon says in the statement.

The new plant, for which AZ expects construction to be complete by late 2013, will also complement an existing manufacturing and supply site in Wuxi New District, Jiangsu Province.

- see the AZ release
- here's the story


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.